Bristol-Myers Squibb Stock News

Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.

The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.

The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.

Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market's reaction to the announcement. The US drugmaker reported that its ACTION-1 Phase 3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progre...

Bristol Myers Squibb scored two Phase 3 wins on Monday in lung disease and cancer. The stock rose, while a key rival plummeted.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACTION--BMS Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ALOFT--Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Myeloma--Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior.